ARCH Venture Partners XII, LLC, 10% Owner at Seaport Therapeutics, Inc. (SPTX), bought 1,100,000 shares at $18.00 ($19.8M) on 2026-05-04, disclosed to the SEC on 2026-05-04.
ARCH Venture Partners XII, LLC executed a $19.8 million purchase of 1.1 million shares at $18.00, marking the largest insider transaction in Seaport Therapeutics' history. This significant capital commitment from a major 10% holder suggests strong conviction in the company's pipeline and potential near-term upside.
The stock is currently trading 25.8% below its 52-week high of $23.00 and just 0.38% above its 52-week low of $17.00, indicating the shares are near the bottom of their recent range.
A 10.2% one-day share price move to $19.84 occurred on May 4, 2026, driving fresh questions about the stock's valuation and momentum.
The company carries a negative forward P/E of -8.78, indicating current losses, and the recent news highlights concerns regarding the stock's valuation relative to its clinical pipeline.
Negative factors outweigh the positive ones.
| Filing → |
| NMRA | BUY | 2023-11-07 | $1.9M | — | Filing → |